The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers.

Ontruzant, which will be marketed in the US by Merck, is a biosimilar to Roche’s Herceptin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is indicated as an adjuvant therapy for HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

The drug can be used to treat patients who have not undergone any prior treatment for metastatic cancers.

Ontruzant is already available in many European markets, as it was approved by the European Commission in November 2017.

Samsung Bioepis senior vice-president and Commercial division head Sang-Jin Pak said: “For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that."

“Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that.”

Last month, the FDA approved Celltrion and Teva Pharmaceutical Industries’ Herceptin biosimilar called Herzuma for the treatment of HER2-overexpressing and metastatic breast cancer.

The regulatory approval was based on a review of foundational analytical similarity, non-clinical, clinical pharmacology, immunogenicity clinical efficacy and safety data.

Trial results showed no clinically meaningful differences in purity, potency and safety between Herzuma and Herceptin for treating patients with HER2-overexpressing breast cancer.

As part of an exclusive alliance formed in October 2016, Celltrion and Teva agreed to commercialise Herzuma in the US and Canada.

One of Roche’s blockbuster drugs, Herceptin generated around CHF7.01bn ($7.04bn) in sales in 2017, according to Reuters. The FDA rejected Pfizer’s Herceptin biosimilar in April last year.